SSO 2025 Countdown
MARCH 27
Days
- :
Hrs
- :
Min
- :
Sec
Showcase your research at SSO 2025!
Abstract Submission: Monday, July 15, 2024 – Monday, October 7, 2024 at 11:59 pm (CST)
The Scientific Program Committee invites you to submit abstracts and videos for the SSO 2025 Annual Meeting, taking place in Tampa, Florida, March 27-29, 2025. All cancer care professionals, both SSO members and non-members, are strongly encouraged to submit their scientific work.
Please review the following guidelines before submitting an abstract. To begin your submission, click the Submit button located at the bottom of this page.
KEY DATES
| October 7, 2024, 11:59 PM (CST) | Abstract Submission Deadline At this time the system will close. Once submission ends, incomplete abstracts cannot be edited or submitted. |
| Mid November 2024 | Abstract Notification Sent to Presenter/Submitter |
| December 2, 2024 | Abstract Author/Title Changes Deadline |
| March 2025 | Abstract Supplement Published in the Annals of Surgical Oncology |
| March 27-29, 2025 | SSO 2025 Meeting: Tampa, FL |
General Submission Guidelines |
|
|
|
|
|
|
|
|
|
There is a non-refundable $60.00 submission fee for each abstract submitted for consideration to SSO 2025. The submission fee must be paid via credit card when submitting your abstract. You will not be able to submit your abstract if the fee is not paid. Abstract fees will not be refunded if you choose to withdraw. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
When submitting an abstract to SSO 2025, the submitting author must comply with the following submission policies. The submitting author is responsible for communicating policies to all involved parties:
|
|
|
|
|
|
The SSO will accept video abstract submissions depicting innovative techniques used to treat common or complex problems, interesting cases or demonstrations, or new therapies or applications for a specific disease site. Case Reports will be considered for Video Abstract submissions. Promotional videos (personal or commercial) will not be considered.
Video abstract submission details must be submitted on the SSO 2025 Abstract site by October 7, 2024.
Instructions for Submitting a Video Abstract:
|
|
As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Per ACCME, there is no minimum financial threshold for financial relationships; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education.
As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.
All identified conflicts of interest must be mitigated, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. Learners must be informed that all relevant financial relationships have been mitigated prior to engaging in accredited education. Learners must also be informed when off label; experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
SSO requires all learners receive disclosure information before engaging in accredited education. Disclosure to learners must include:
• The first and last name of individual with the financial relationship.
• The names of the ineligible companies with which they have relationships.
• The nature of the relationships.
• A statement that all relevant financial relationships have been mitigated.
Disclosure to learners must not include ineligible companies’ corporate or product logos, trade names, or product group messages.
SSO must inform learners about planners, faculty, and others in control of content (either individually or as a group) with no relevant financial relationships with ineligible companies.
Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ACCME does not consider providers of clinical service directly to patients to be ineligible. |
|
Copyright Assignment: I represent and warrant that the attached abstract and any later-created Presentation is/will be original work. I understand that in the event my abstract is accepted by SSO, all materials related to my abstract and Presentation may by used by SSO, in any form, for educational purposes including, but not limited to, recording my oral presentation of this material; the sale of this recording; and the printing and/or electronic publication of this material, excerpts, or abstracts. I control all rights to the abstract and Presentation which is/will be created, have the authority to assign copyrights, and hereby agree to assign to SSO all copyrights in the abstract and Presentation in any medium if my abstract and Presentation is accepted by SSO. |
Abstract Selection Guidelines |
|
All abstracts are subject to a blind peer-review by members of the following:
All reviewers, session planners and invited faculty will be required to disclose all financial relationships through the online system, helping to ensure high-quality, unbiased presentations and compliance with CME regulations. In addition, all authors must disclose all financial relationships during the submission process before their abstract will be considered and graded. |
|
|
|
Each abstract submitter will receive an email acknowledging receipt of the abstract after initiating a submission and after completing a submission. If the abstract is selected for inclusion in SSO 2025, the presenting author listed will receive an invitation to participate from the Scientific Program Committee by the middle of November 2024.
Abstracts may not be withdrawn after acceptance. You may select a replacement presenter if you are unable to present your abstract in-person. All author/title changes must be communicated prior to November 15, 2024 in order to be included in the Abstract edition of the Annals of Surgical Oncology or meeting materials.
To withdraw an abstract, the presenter must notify the SSO office by the end of the abstract review. Once an abstract has been accepted for the program it may no longer be withdrawn. Prior to submitting your abstract(s), please ensure you and/or one of your team of authors has secured proper funding sources to present at the meeting. Presenters of the accepted abstracts must register for the meeting and are responsible for their own travel expenses as well as the meeting registration fee. |
|
|
|
SSO leadership believes that research presented at SSO’s annual meeting should be published in the Annals of Surgical Oncology (ASO) and the Surgical Oncology Insight (SOI), the official journals of the SSO. The following guidance provides submission information; detailed information will be provided to accepted abstract presenters.
|
|
|